Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
BENGALURU, Nov 7 (Reuters) - Delhi was the world's most polluted major city on Saturday…
The milestone marks a significant chapter in the company’s growth journey, transitioning from the BSE…
Nov 7 (Stats Perform) - Results from the NCAAB games on Friday (home team in…
Nov 7 (Stats Perform) - Standings from the NBA games on Saturday Eastern Conference Atlantic…
Vadodara (Gujarat) [India], November 6: Parul University in Gujarat has moved into the 791-800 band…
Nov 7 (Stats Perform) - Results from the NCAAB games on Friday (home team in…